Suppr超能文献

评价外显子组测序标准在儿童医院的医院管理和保险授权中的应用。

Evaluation of Exome Sequencing Criteria for Hospital Stewardship and Insurance Authorization at a Pediatric Hospital.

机构信息

From the Department of Laboratories (Wittowski, Clowes Candadai, Perrone, Gallego, Conta, Dickerson), Seattle Children's Hospital, Seattle, Washington.

Patient-Centered Laboratory Utilization Guidance Services (PLUGS) (Clowes Candadai, Conta, Dickerson), Seattle Children's Hospital, Seattle, Washington.

出版信息

Arch Pathol Lab Med. 2022 Jan 1;146(1):107-111. doi: 10.5858/arpa.2020-0572-OA.

Abstract

CONTEXT.—: Genomic molecular testing practices in a pediatric tertiary care institution can vary in utility by patient indication.

OBJECTIVE.—: To evaluate exome sequencing (ES) ordering practices and the effects of applying criteria to support ES stewardship. Exome sequencing can provide molecular diagnostic information for patients with known or suspected genetic diseases, but it is relatively expensive, and the cost is often borne by patients, institutions, and payers.

DESIGN.—: We examined ordering patterns of ES approved by board-certified geneticists at our tertiary pediatric care center, as well as preauthorization outcomes for ES requests. We compared positivity rates among patients by patient phenotype, composite insurance coverage criteria, and insurance preauthorization outcome.

RESULTS.—: Patients who met composite coverage criteria were more likely to receive a positive result from ES compared to patients who did not meet composite coverage criteria, though this trend was not statistically significant. There was no significant difference in ES results between patients who were denied or not denied preauthorization by insurance payers.

CONCLUSIONS.—: Insurance payers should consider implementing and/or expanding coverage criteria for ES, and institutions should implement stewardship programs to support appropriate ES practices.

摘要

背景

儿科三级医疗机构的基因组分子检测实践在患者适应证方面的实用性可能存在差异。

目的

评估外显子组测序(ES)的测序实践,并评估应用标准来支持 ES 管理的效果。外显子组测序可为已知或疑似遗传疾病的患者提供分子诊断信息,但它相对昂贵,且费用通常由患者、医疗机构和支付方承担。

设计

我们检查了我们三级儿科护理中心经 board-certified geneticists 批准的 ES 测序模式,以及 ES 请求的预授权结果。我们比较了不同患者表型、综合保险覆盖标准和保险预授权结果的阳性率。

结果

符合综合覆盖标准的患者比不符合综合覆盖标准的患者更有可能从 ES 中获得阳性结果,尽管这种趋势没有统计学意义。在被保险支付方拒绝或未拒绝预授权的患者之间,ES 结果没有显著差异。

结论

保险支付方应考虑为 ES 制定和/或扩大覆盖标准,医疗机构应实施管理计划以支持适当的 ES 实践。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验